Boehringer Ingelheim

This study tests whether combining several drugs can shrink tumors in adults with head and neck cancer that has come back or spread. Participants receive up to three antibodies: two that help the immune system fight cancer, one that blocks tumor growth signals, and one that cuts …

This early-stage study tests a new medicine called BI 3000202 in 16 adults with rare immune disorders like Aicardi-Goutières syndrome. Participants take the drug as tablets for 40 weeks to see if it is safe and how the body processes it. The goal is to control the disease, not cu…

This study looks at the safety and effectiveness of taking JARDIANCE® tablets every day for a long time in people with chronic kidney disease. About 1,024 patients in Japan who are prescribed the drug for kidney disease will be followed in real-world settings. Researchers will tr…

This early-phase study tests a new experimental drug called BI 764532 (obrixtamig) combined with standard chemotherapy and immunotherapy for adults with extensive-stage small cell lung cancer. The main goal is to find the highest safe dose of BI 764532 when given with standard tr…

This study looks at whether a daily pill called BI 1291583 is safe and helps control symptoms of bronchiectasis, a long-term lung condition. About 268 adults who were in earlier studies of this drug will take low, medium, or high doses for up to one year. Researchers will track s…

This study tests a new medicine called BI 764524 in 187 adults with moderate to severe diabetic retinopathy, a diabetes-related eye disease. Participants receive different numbers of eye injections over a year, and doctors compare their eye health to those getting a sham or stand…

This study tests whether the drug spesolimab can safely and effectively treat repeated flares of generalized pustular psoriasis (GPP), a serious skin condition. About 42 adults with a history of GPP flares will receive a single infusion of spesolimab at the start of a flare, with…

This early-phase study tests a new experimental drug, BI 765179, in adults with advanced solid tumors or head and neck cancer that has not responded to standard treatments. The study has two parts: the first finds the safest dose of BI 765179 alone or with another drug (ezabenlim…

This study tests a new medicine called BI 771716 against an approved treatment (pegcetacoplan) for geographic atrophy, an advanced form of age-related macular degeneration that causes blind spots. About 202 adults aged 50 and older will receive eye injections every 4 weeks for ov…

This study tests a new medicine, BI 3032950, in adults with moderate to severe ulcerative colitis who haven't been helped by other treatments. The trial has two parts: first, the medicine is given through an IV every 4 weeks for 12 weeks, then as a shot under the skin every 4 wee…

This study tests an experimental drug (BI 765049) alone or with another drug (ezabenlimab) in Asian adults with advanced cancers like stomach, lung, pancreatic, colorectal, head and neck, or liver cancer. The goal is to find the highest safe dose and see if the drugs can shrink t…

This study looks at medical records of nearly 8,000 people with HER2-altered metastatic breast cancer in the United States. Researchers want to see what treatments patients actually receive and how long they live. The goal is to understand real-world care patterns, not to test a …

This study tests a new formulation of survodutide, a medicine being developed for obesity and liver conditions. About 100 healthy adults aged 18-65 with a BMI between 27 and 39.9 will receive weekly injections of either the current or new formulation for 28 weeks. Researchers wil…

This study follows 2,000 people with systemic sclerosis (scleroderma) who have lung scarring (interstitial lung disease) and are taking nintedanib. Researchers want to see how the drug affects lung function, quality of life, and survival over time. Participants are already part o…

This study tracks over 230,000 adults with type 2 diabetes to see how well empagliflozin works in everyday medical practice. Researchers are comparing it to another class of diabetes drugs (DPP-4 inhibitors) to measure real-world effects on heart attacks, strokes, heart failure, …